Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. drug and vaccine manufacturing
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Drug And Vaccine Manufacturing Articles & Analysis: Older

57 news found

Protheragen-ING Announces Lyophilized Flash-release Formulations Development Capabilities

Protheragen-ING Announces Lyophilized Flash-release Formulations Development Capabilities

Protheragen-ING has recently announced its ability to provide freeze-drying flash-release formulation development services to clients involved in drug discovery and development worldwide. Lyophilized flash-release formulations are advanced drug delivery systems that incorporate the benefits of both lyophilization and flash-release technologies. “Whether customers are trying to develop a ...

ByProtheragen-ING


Protheragen-ING Joins the DCAT Association

Protheragen-ING Joins the DCAT Association

In exciting news, Protheragen-ING officially become a member of the Drug, Chemical & Associated Technologies (DCAT) Association. This move marks a significant milestone for Protheragen-ING and highlights the company's commitment to collaboration, innovation, and growth within the global pharmaceutical community. By joining forces with DCAT, Protheragen-ING, a supplier of Vitamin C Products, ...

ByProtheragen-ING


Alfa Chemistry Leads the Way to Unleash Power of Computational Solutions in Solid State Chemistry for Pharmaceutical Research   

Alfa Chemistry Leads the Way to Unleash Power of Computational Solutions in Solid State Chemistry for Pharmaceutical Research  

In the ever-evolving field of pharmaceutical research, the hunt for effective drugs often rests on the ability to understand and manipulate the solid-state properties of compounds. Alfa Chemistry, a leading provider of research and development solutions, is taking the lead in harnessing the power of computational solutions in solid state chemistry to facilitate pharmaceutical research. ...

ByAlfa Chemistry


CD Formulation: Prescription Screening Process Analysis Provides New Possibilities for Pharmaceutical Industry

CD Formulation: Prescription Screening Process Analysis Provides New Possibilities for Pharmaceutical Industry

CD Formulation, a leading CRO specialized in pharmaceutical formulation, has launched a new prescription screening process analysis service for both existing and new customers across the globe. The goal is to provide drug manufacturers with accurate and reliable results. Moreover, the technology used in this process is capable of detecting impurities and other contaminants in prescription drug ...

ByCD Formulation


BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate

BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate

BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the ...

ByBOC Sciences


BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Partners

BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Partners

In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands. Innovations in manufacturing processes, more complicated formulations, and increasingly complex global supply chains are just some of the factors making it more difficult for companies to ...

ByBOC Sciences


EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.

EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.

LOTTE BIOLOGICS and EXCELLGENE today announced the signing of a Memorandum of Understanding to collaborate in the biopharmaceutical Contract Development Organization (CDO) business. With this agreement, LOTTE BIOLOGICS will be able to proactively promote its CDO business by attracting a large number of customers ahead of its long-term strategy of expanding its Syracuse plant and constructing a ...

ByExcellGene SA


Lifespin Announces Expansion of Laboratory Testing Capability

Lifespin Announces Expansion of Laboratory Testing Capability

Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...

ByLifespin GmbH


Revolutionizing Biopharma manufacturing

Revolutionizing Biopharma manufacturing

LenioBio develops efficient and sustainable technologies for protein expression. Company with a clear goal: To simplify protein production and accelerate the delivery of drugs to patients. Revolutionizing Biopharma manufacturing LenioBio develops efficient and sustainable technologies for protein expression. Company with a clear goal: To simplify protein production and accelerate the delivery of ...

ByLenioBio GmbH


Peer reviewed publications reporting the effectiveness of the Kurve intranasal insulin product

Peer reviewed publications reporting the effectiveness of the Kurve intranasal insulin product

Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading developer of nasal drug delivery devices. ...

ByKurve Therapeutics, Inc.


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...

ByLumen Bioscience, Inc.


InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors ...

ByInMed Pharmaceuticals Inc.


InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors ...

ByInMed Pharmaceuticals Inc.


CDMO Services Released by Alfa Chemistry Offer New Possibilities for Pharmaceutical Development & Manufacturing

CDMO Services Released by Alfa Chemistry Offer New Possibilities for Pharmaceutical Development & Manufacturing

Known for its competence, responsibility, and innovative capability in chemical supply, Alfa Chemistry recently unveiled its new role as a CDMO service provider for pharmaceutical companies worldwide. Contract Development and Manufacturing Organization, abbreviated as CDMO, is a preferential way for a majority of pharmaceutical companies to outsource ongoing drug development and drug ...

ByAlfa Chemistry


Scandinavian Biopharma welcomes Anna Sumic to the position as Drug Substance and Drug Product Manufacturing Specialist

Scandinavian Biopharma welcomes Anna Sumic to the position as Drug Substance and Drug Product Manufacturing Specialist

Scandinavian Biopharma continues to strengthen its organization in manufacturing and is pleased to welcome Anna Sumic as our new DS & DP Manufacturing Specialist. Anna has a Master of Science in Chemistry and Chemical Engineering from KTH, Royal Institute of Technology, with 15 years of experience within the pharmaceutical industry. She is joining us from AFRY, a consulting company, where ...

ByScandinavian Biopharma


XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study

XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study

XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). Over ...

ByXPhyto Therapeutics Corporation


Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001

Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001

The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics ...

ByEnalare Therapeutics Inc.


Alfa Chemistry Launches Donepezil for Alzheimer's Disease Research

Alfa Chemistry Launches Donepezil for Alzheimer's Disease Research

Alfa Chemistry, a long-term partner for many pharmaceutical companies, universities, and research institutions, recently announced to offer donepezil, a synthetic active pharmaceutical ingredient (API) that can be used in pharmaceutical preparation for the treatment of Alzheimer's disease. API refers to the biologically active component of a drug product. In recent decades, the great importance ...

ByAlfa Chemistry


CD Formulation Enables Customized Synthesis Service for Osmotic Pressure Regulators for Drug Development

CD Formulation Enables Customized Synthesis Service for Osmotic Pressure Regulators for Drug Development

Normal cell function requires the maintenance of osmotic pressure. Therefore, in drug manufacturing, osmotic pressure regulators should be added to the formulation to avoid tissue damage. The US-based CRO company CD Formulation recently announced its ability to synthesize osmotic pressure regulators to suit the needs of different drug projects. These osmotic pressure regulators will help ...

ByCD Formulation


New Startup Makes Developing Gene Therapies Faster and Easier

New Startup Makes Developing Gene Therapies Faster and Easier

Today, cell and gene therapies treat and could even cure terminal diseases like leukemia and spinal muscular atrophy, but unlocking their full potential is still a challenge for therapy developers. Both types of therapies rely on living cells comprised of hundreds of thousands of biomolecules to work in unison. And in order for therapy developers to meet safety and production ...

ByCell Manufacturing Technologies (CMaT)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT